1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Asset Purchase
1.2.3 Collaborative R&D
1.2.4 Joint Venture
1.2.5 Licensing
1.2.6 Other
1.3 Market by Application
1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Medical Care
1.3.5 Education and Research
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2018-2029)
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region
2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2018-2023)
2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2024-2029)
2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics
2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends
2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue
3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2018-2023)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2018-2023)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2022
3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2018-2023)
4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2024-2029)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application
5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2018-2023)
5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 3SBio
11.1.1 3SBio Company Detail
11.1.2 3SBio Business Overview
11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.1.5 3SBio Recent Development
11.2 4D Pharma
11.2.1 4D Pharma Company Detail
11.2.2 4D Pharma Business Overview
11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.2.5 4D Pharma Recent Development
11.3 Abbvie
11.3.1 Abbvie Company Detail
11.3.2 Abbvie Business Overview
11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.3.5 Abbvie Recent Development
11.4 Abzena
11.4.1 Abzena Company Detail
11.4.2 Abzena Business Overview
11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.4.5 Abzena Recent Development
11.5 Adaptive Biotechnologies
11.5.1 Adaptive Biotechnologies Company Detail
11.5.2 Adaptive Biotechnologies Business Overview
11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.5.5 Adaptive Biotechnologies Recent Development
11.6 Aeglea BioTherapeutics
11.6.1 Aeglea BioTherapeutics Company Detail
11.6.2 Aeglea BioTherapeutics Business Overview
11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.6.5 Aeglea BioTherapeutics Recent Development
11.7 Agenus Bio
11.7.1 Agenus Bio Company Detail
11.7.2 Agenus Bio Business Overview
11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.7.5 Agenus Bio Recent Development
11.8 Ascension
11.8.1 Ascension Company Detail
11.8.2 Ascension Business Overview
11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.8.5 Ascension Recent Development
11.9 Ascentage Pharma
11.9.1 Ascentage Pharma Company Detail
11.9.2 Ascentage Pharma Business Overview
11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.9.5 Ascentage Pharma Recent Development
11.10 Aslan Pharma
11.10.1 Aslan Pharma Company Detail
11.10.2 Aslan Pharma Business Overview
11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.10.5 Aslan Pharma Recent Development
11.11 Telix Pharmaceuticals
11.11.1 Telix Pharmaceuticals Company Detail
11.11.2 Telix Pharmaceuticals Business Overview
11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.11.5 Telix Pharmaceuticals Recent Development
11.12 Basilea Pharmaceutica
11.12.1 Basilea Pharmaceutica Company Detail
11.12.2 Basilea Pharmaceutica Business Overview
11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.12.5 Basilea Pharmaceutica Recent Development
11.13 Bavarian Nordic
11.13.1 Bavarian Nordic Company Detail
11.13.2 Bavarian Nordic Business Overview
11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.13.5 Bavarian Nordic Recent Development
11.14 Baxalta
11.14.1 Baxalta Company Detail
11.14.2 Baxalta Business Overview
11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.14.5 Baxalta Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Cantargia
11.16.1 Cantargia Company Detail
11.16.2 Cantargia Business Overview
11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.16.5 Cantargia Recent Development
11.17 Apollomics
11.17.1 Apollomics Company Detail
11.17.2 Apollomics Business Overview
11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.17.5 Apollomics Recent Development
11.18 Chiome Bioscience
11.18.1 Chiome Bioscience Company Detail
11.18.2 Chiome Bioscience Business Overview
11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.18.5 Chiome Bioscience Recent Development
11.19 Clovis Oncology
11.19.1 Clovis Oncology Company Detail
11.19.2 Clovis Oncology Business Overview
11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.19.5 Clovis Oncology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
